This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Learning Zone 316 Events 27 News 17110 Drugs 62387 Trials 8088 Guidelines 836 Journals 3403
Filter results
Sort by:
Relevance
to
Latest drug news
Drug news
16/04/15

Data on Invega Sustenna (paliperidone palmitate) in Schizophrenia published in JCP-Janssen Pharmaceuticals

A study published in The Journal of Clinical Psychiatry shows that long-acting Invega Sustenna (paliperidone palmitate), from Janssen Pharmaceuticals, was...

  • 1 min read
Journals
Journal
05/01/18

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.

This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone.

  • 1 min read
  • Source: Neuropsychiatric Disease and Treatment
Clinical trials
Clinical trial
01/05/10

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined...

  • 2 min read
  • Source: Clinicaltrials.gov
Journals
Journal
23/03/18

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes.

There are currently no guidelines for switching patients from oral risperidone to paliperidone palmitate (Invega Sustenna®).

  • 1 min read
  • Source: The Mental Health Clinician
Latest drug news
Drug news
05/04/16

CHMP recommends Trevicta (paliperidone palmitate a 3-monthly injection) to treat schizophrenia.-Janssen Cilag

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
22/12/22

INVEGA HAFYERA PALIPERIDONE PALMITATE 1560 mg/5mL Janssen Pharmaceuticals, Inc

  • 8 min read
Latest drug news
Drug news
02/06/16

EMA approves Trevicta (paliperidone palmitate a three monthly injection) for the maintenance treatment of schizophrenia.- Janssen Cilag

Janssen-Cilag International NV announced that the European Commission (EC) has approved the use of Trevicta (paliperidone palmitate a three monthly...

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
22/12/22

INVEGA HAFYERA PALIPERIDONE PALMITATE 1092 mg/3.5mL Janssen Pharmaceuticals, Inc

  • 8 min read
EMC Drug Feed
Drug information
03/02/23

Paliperidone Mercury Pharma 50 mg prolonged-release suspension for injection in pre-filled syringe

Paliperidone Mercury Pharma Prolonged Release suspension for injection is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Paliperidone Mercury Pharma Prolonged Release suspension for injection may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

  • 1 min read
EMC Drug Feed
Drug information
03/02/23

Paliperidone Mercury Pharma 25 mg prolonged-release suspension for injection in pre-filled syringe

Paliperidone Mercury Pharma Prolonged Release suspension for injection is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Paliperidone Mercury Pharma Prolonged Release suspension for injection may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

  • 1 min read
See more